<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37369195</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus without systemic activity.</ArticleTitle><Pagination><StartPage>1123</StartPage><EndPage>1125</EndPage><MedlinePgn>1123-1125</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231186718</ELocationID><Abstract><AbstractText>Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an uncommon subtype of peripheral neuropathy, especially in systemic lupus erythematosus (SLE). We report a case of SLE presenting with CIDP successfully treated. The patient presented with bilateral, progressive, ascending, sensory, and motor neuropathy. Electrodiagnostic tests reported active motor and sensitive demyelinating polyneuropathy, and the diagnosis of CIDP was confirmed according to the European Federation of Neurological Societies/Peripheral Nerve Society criteria. Initial management with intravenous immunoglobulin and high-dose steroids was administered, then 6-month intravenous cyclophosphamide was initiated with improvement according to clinical scales. In conclusion, CIDP in SLE is rare, reported in just 0.2%. Immunosuppressive therapy should be considered whether initial improvement is not evidenced, as seen in our case requiring cyclophosphamide; interestingly, systemic activity was in remission as the peripheral nervous system is not part of neurological compromise, and we suggest evaluating this unusual presentation into rheumatological practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calixto</LastName><ForeName>Omar-Javier</ForeName><Initials>OJ</Initials><Identifier Source="ORCID">0000-0002-9734-025X</Identifier><AffiliationInfo><Affiliation>Clinical Immunology Group, Department of Rheumatology and Immunology, Hospital Militar Central, Bogot&#xe1;, Colombia.</Affiliation><Identifier Source="RINGGOLD">150243</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Immunology Group, School of Medicine, Universidad Militar Nueva Granada, Bogot&#xe1;, Colombia.</Affiliation><Identifier Source="RINGGOLD">469630</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poveda</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hospital Militar Central, Bogot&#xe1;, Colombia.</Affiliation><Identifier Source="RINGGOLD">150243</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meneses-Toro</LastName><ForeName>Maria Alejandra</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Clinical Immunology Group, Department of Rheumatology and Immunology, Hospital Militar Central, Bogot&#xe1;, Colombia.</Affiliation><Identifier Source="RINGGOLD">150243</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Immunology Group, School of Medicine, Universidad Militar Nueva Granada, Bogot&#xe1;, Colombia.</Affiliation><Identifier Source="RINGGOLD">469630</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vera-Parra</LastName><ForeName>Edward Camilo</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Clinical Immunology Group, Department of Rheumatology and Immunology, Hospital Militar Central, Bogot&#xe1;, Colombia.</Affiliation><Identifier Source="RINGGOLD">150243</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Immunology Group, School of Medicine, Universidad Militar Nueva Granada, Bogot&#xe1;, Colombia.</Affiliation><Identifier Source="RINGGOLD">469630</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero-S&#xe1;nchez</LastName><ForeName>Consuelo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Immunology Group, School of Medicine, Universidad Militar Nueva Granada, Bogot&#xe1;, Colombia.</Affiliation><Identifier Source="RINGGOLD">469630</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Cellular and Molecular Immunology Group/ INMUBO, Universidad El Bosque, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guzman Molano</LastName><ForeName>Luisa Fernanda</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hospital Militar Central, Bogot&#xe1;, Colombia.</Affiliation><Identifier Source="RINGGOLD">150243</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bello-Gualtero</LastName><ForeName>Juan Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Clinical Immunology Group, Department of Rheumatology and Immunology, Hospital Militar Central, Bogot&#xe1;, Colombia.</Affiliation><Identifier Source="RINGGOLD">150243</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Immunology Group, School of Medicine, Universidad Militar Nueva Granada, Bogot&#xe1;, Colombia.</Affiliation><Identifier Source="RINGGOLD">469630</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020277" MajorTopicYN="Y">Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017933" MajorTopicYN="N">Peripheral Nervous System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chronic inflammatory demyelinating polyradiculoneuropathy</Keyword><Keyword MajorTopicYN="N">immunosuppressive therapy</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>27</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37369195</ArticleId><ArticleId IdType="doi">10.1177/09612033231186718</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>